Developer docs
API playgroundTry for free, no card

Search company profiles

Qure AI

Full company profile

uuid0000433

Namestring
Qure AI
Legal namestring
Qure.ai Technologies Private Limited
Websiteurl
qure.ai
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Qure.ai Technologies Private Limited is a Mumbai-headquartered healthcare AI company founded in 2016 by Prashant Warier that develops deep-learning computer-vision models for automated interpretation of radiology exams (chest X-ray, head CT, chest CT, MSK X-ray) and, more recently, ultrasound. Its product portfolio is anchored by qXR (chest X-ray reporting with 26 FDA-cleared indications across 9 products), supported by qER (stroke/TBI head CT), qCT LN Quant (lung nodule management), qMSK, qTrack (care coordination), qScout (population surveillance), and the Aira clinical AI co-pilot for LMICs; algorithms are trained on more than 1 billion medical images and are deployed as cloud or on-premise services integrated with PACS/RIS and OEM imaging platforms.

The company monetizes primarily through enterprise SaaS subscriptions to hospital systems and NHS trusts, per-study/per-deployment licensing to OEM and platform partners (Fujifilm, Siemens Healthineers, Philips, Blackford, Medtronic, Nuance), managed-services contracts with national and state public health programs (Telangana, Goa, Maharashtra, Lesotho, Mozambique, Oman), professional-services arrangements with pharma and life-sciences customers (AstraZeneca, Project Data Sphere, Roche Startup Creasphere), and non-dilutive grant funding (Gates Foundation $8M, SBRI/NHS £3.2M). Its go-to-market combines direct enterprise sales (partner@qure.ai) with OEM embedding, channel resellers (Medica Group, InHealth, USARAD, Strategic Radiology, Unilabs, deepc, Healthcare Imaging Services), NGO/global-health partners (PATH, VillageReach, IHVN, CIDRZ), and event-led demand generation across RSNA, ASCO, ATS, and the India AI Impact Summit.

Qure.ai reports reaching 45M+ lives across 105+ countries via 5,500+ sites, holds 40 patents, and is referenced in a 2026 source as a subsidiary of Fractal Analytics; it has raised approximately $130M cumulatively, including a $65M Series D in September 2024 led by Lightspeed and 360 ONE Asset. The company maintains offices in Mumbai, Bengaluru, New York, and Birmingham, and counts the FDA, EU MDR, Health Canada, and the WHO (for autonomous TB screening) among its regulatory endorsements.

Short descriptiontext

Qure.ai is a Mumbai-headquartered healthcare AI company that builds FDA-cleared deep-learning algorithms to interpret chest X-rays, head CTs, chest CTs, and ultrasounds, deployed across 5,500+ sites in 105+ countries via direct hospital sales, OEM embedding, and government public-health programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, radiology AI software, clinical decision support, lung cancer detection, tuberculosis screening
Industry3 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Software Publishers51321
  • Diagnostic Imaging Centers621512
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model5 records
1Enterprise SaaS subscriptions
TypeSubscription Recurring
Description

Subscription-based deployment of qXR, qER, qCT, qTrack, and qMSK AI platforms to hospital systems, NHS trusts, teleradiology firms, and government health programs. Recurring contracts tied to deployment scope, volume, and integrations.

qure.ai
2OEM/embedded licensing
TypeLicensing Royalties
Description

Per-study/per-deployment licensing to OEM and platform partners including Fujifilm (REiLI), Siemens Healthineers, Philips, Blackford, Medtronic, and Nuance, who embed Qure.ai algorithms into their own products and services.

qure.ai
3Government and public health program contracts
TypeManaged Services
Description

Direct contracts with state health ministries and national TB/lung cancer programs (Telangana, Goa, Maharashtra, Bihar, Lesotho, South Africa, Mozambique, Philippines) for population-scale AI screening deployments.

qure.ai
4Pharma & life sciences clinical trial services
TypeProfessional Services
Description

AI-derived biomarker and care coordination services for pharmaceutical R&D and clinical trials, including partnership with Project Data Sphere on autoRECIST for tumor burden measurement and AstraZeneca A.Catalyst Network collaborations.

qure.ai
5Grants and non-dilutive funding
TypeProfessional Services
Description

Multi-million-dollar grants from foundations such as the Gates Foundation ($8M for AI-powered point-of-care ultrasound and open-source multi-modal lung health database) and SBRI Healthcare / NHS Cancer Programme (£3.2M).

linkedin.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based enterprise contracts via partner@qure.ai
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; tailored to scope, modality, volume, and integrations.

qure.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1qXR
Description

Chest X-ray AI reporting and triage solution; includes sub-products such as qXR-Detect, qXR-LN (lung nodule detection), qXR-PTX-PE (pneumothorax and pleural effusion), and qXR-CTR (heart failure risk indicator).

qure.ai
+7 more records
Core offering1 text field

Qure AI develops deep-learning medical imaging software that interprets chest X-rays, head CTs, chest CTs, and musculoskeletal X-rays for clinical decision support. Its portfolio (qXR, qER, qCT LN Quant, qTrack, qMSK, Aira, qXR-CTR) is sold to hospitals, NHS trusts, teleradiology firms, government public-health programs, OEM imaging vendors, and pharmaceutical/life-sciences organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 26.7% of initially missed lung nodules detected on routine chest X-rays using qXR-LN, including 40% of early-stage cancers and 50% of missed Stage 1A nodules (University Hospitals Cleveland Medical Center study)
+9 more records
Product overview1 text field

Qure.ai offers a single unified AI healthcare platform combining a portfolio of deep-learning medical imaging products deployed across 5,500+ sites in 105+ countries. The portfolio is anchored by qXR (chest X-ray reporting) as the core imaging product, supported by qER (stroke and TBI head CT analysis), qMSK (musculoskeletal X-ray), and Heart Failure (qXR-CTR) modules, with qTrack providing care coordination and TB cascade management. The Lung Nodule Management module (including qCT LN Quant) extends the platform to end-to-end lung cancer care, while Aira acts as a multi-disease clinical AI co-pilot for resource-constrained settings. Together these products cover the full clinical workflow from screening and triage to diagnosis, quantification, and longitudinal case management.

Product and service8 records
1qXR (Chest X-ray Reporting)
CategoryMedical Imaging AI
2qER (Stroke & Traumatic Brain Injury)
CategoryMedical Imaging AI
3Lung Nodule Management (qCT LN Quant)
CategoryMedical Imaging AI
4qTrack (TB Care Cascades)
CategoryMedical Imaging AI
5qMSK (Musculoskeletal X-Ray Reporting)
CategoryMedical Imaging AI
6Heart Failure (qXR-CTR)
CategoryMedical Imaging AI
7Aira (Multi-Disease Clinical AI Co-Pilot)
CategoryMedical Imaging AI
8Qure AI App
CategoryMedical Imaging AI
Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership33 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Multi-program strategic partnership under the EDISON Alliance's 1 Billion Lives Challenge to screen 5 million patients by 2025 for lung cancer risk in Colombia, El Salvador, India, and other LMICs. Joint lung cancer screening programs in Telangana (20 hospitals), Goa, Philippines, and Latin America. Co-development of A.Catalyst Network initiatives and combined pharma-AI care pathways.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Partnership to expand access to Qure.ai's lung cancer detection and management suite in the United States (announced November 2025). Joint go-to-market leveraging Microsoft's cloud and healthcare channels for US-based deployments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hub-and-spoke stroke care partnership in India integrating Qure.ai's AI CT analysis with Medtronic's stroke network to expedite treatment for nearly two million stroke patients annually.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-developing autoRECIST AI for imaging-based tumor burden measurements in oncology clinical trials and routine cancer care, announced January 2024.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joined Roche's Startup Creasphere APAC program to co-create strategies supporting clinicians and improving patient outcomes in APAC through early detection enabled by AI (October 2024).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to boost early detection of lung cancer in India, integrating Qure.ai AI solutions with J&J Medtech lung cancer initiatives (announced May 2025).

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

Validated on Fujifilm's AI-enabled platform REiLI and partnered with Fujifilm and IHVN to accelerate TB screening in rural Nigerian communities (2021, 2023). Co-delivered solutions across global health programs.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

Validated partner on Siemens Healthineers AI portfolio; collaboration with the Global Fund to accelerate AI adoption for TB diagnosis (2023); recipient of Siemens Healthineers Startup Award 2024.

Strategic tierCoreTypeTechnology or Integration
Description

Partner logo displayed on the Qure.ai homepage indicating technology integration and co-distribution across Philips imaging and AI portfolio.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a distribution/integration partner on the Qure.ai homepage, deploying Qure.ai neurocritical AI solutions into A&E settings including Milton Keynes University Hospital.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to strengthen Mozambique's AI-enabled pandemic preparedness system, announced May 2026.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Province-wide partnership to advance early lung cancer detection across New Brunswick, Canada, announced December 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Launched an AI-enabled Lung Nodule Clinic with Qure.ai to strengthen early lung cancer detection and lung health, announced November 2025.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Deployed AI-Powered Chest CT for early lung cancer detection via Qure.ai, announced April 2025.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Public-private partnership with AstraZeneca and Qure.ai to perform AI-enabled chest X-ray screening; over 1 lakh X-rays reviewed identifying 18 lung cancer cases. Extended MoU announced April 2025.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

MoU with AstraZeneca Pharma India and Qure.ai to deploy AI-powered lung cancer screening across 20 public hospitals, announced April 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Launched AI Innovation Centre for Medical Imaging in September 2022 and extended collaboration in December 2024 for early lung cancer detection.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to empower care teams with AI-enhanced patient care workflows by integrating Qure.ai AI into deepc's platform (November 2023).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Joined Nuance Precision Imaging Network to enhance patient outcomes with AI-integrated workflows for care teams (April 2023).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership integrating Qure.ai augmented intelligence into Medica Group's teleradiology services for the UK, supporting faster stroke and neurocritical reporting.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to enhance quality of telereporting services with Qure.ai's AI-powered chest X-ray solution (May 2023).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership expanded Qure.ai presence into US teleradiology market (October 2023).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Collaboration to assist radiology workflows with Qure.ai AI-powered imaging (June 2024).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Unilabs signed on Qure.ai for triaging chest X-rays (July 2022).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to improve access to breast cancer detection through AI (March 2023).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Strategic collaboration announced August 2023.

27Healthcare Imaging Services (Australia)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to bring AI chest X-ray diagnosis to Australia (July 2021).

qure.ai
28Nordic MedTech
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to provide radiology practices with Qure.ai AI technology (July 2020).

qure.ai
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Implementation partner for AI-enabled chest X-ray solution for TB and COVID-19 screening in Maharashtra through Unitaid funding (2021-2023). Joint lung cancer early detection initiative with AstraZeneca in LMICs (2022).

30USAID
Strategic tierCoreTypeStrategic or Co-development Partner
Description

USAID-supported SAMRIDH Healthcare Blended Finance Facility supports Qure.ai to strengthen India's healthcare systems (April 2022); joint program to enhance diagnostics (September 2023).

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Partnered with Fujifilm and Qure.ai to accelerate TB screening in rural Nigerian communities (August 2022).

32CIDRZ (Centre for Infectious Disease Research in Zambia)
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Partnered with Qure.ai for TB screening (July 2022).

qure.ai
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Qure.ai is referenced as a Fractal Analytics subsidiary in Fractal's Q4 FY26 commentary (May 2026). Fractal showcased a partnership with Qure.ai for rapid TB detection in radiology at the India AI Impact Summit 2026.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korea-based AI medical imaging company with flagship INSIGHT CXR for chest X-ray triage and Lunit SCOPE for biomarker analysis — directly competing with Qure.ai's qXR in chest X-ray AI for lung cancer and TB detection across hospital systems.

2Nanox AI (formerly Zebra Medical Vision)
TypeDirect peer
Description

AI imaging algorithms for chest, bone, and other modalities distributed through the Nanox platform; overlaps with Qure.ai's qXR chest X-ray and broader imaging AI footprint.

TypeOthers
Description

Medical imaging AI aggregator and distribution platform that resells/embeds Qure.ai algorithms alongside competitor algorithms; relevant as a channel peer and AI marketplace operator shaping hospital AI procurement.

TypeDirect peer
Description

AI medical imaging company offering a suite of FDA-cleared algorithms for CT/MRI triage across multiple findings; directly comparable to Qure.ai's qER and broader imaging AI strategy aimed at hospital radiology workflows.

TypeDirect peer
Description

Comprehensive AI radiology platform covering chest X-ray, CT, and head CT findings — closely comparable to Qure.ai's multi-modality imaging portfolio and enterprise hospital go-to-market.

TypeEmerging player
Description

AI mammography (MammoScreen) and breast cancer detection — overlaps with Qure.ai's life sciences and screening thesis; also a named Qure.ai partner, indicating close ecosystem positioning.

TypeBroad incumbent
Description

Global imaging and health technology incumbent with its own AI imaging suite; operates as a Qure.ai technology and distribution partner, and competes broadly in radiology AI decision support.

TypeBroad incumbent
Description

Global imaging modality OEM with its own AI-Rad Companion portfolio and validated-Qure.ai partner on REiLI equivalent; relevant as both a broad incumbent competitor and an OEM distribution channel for Qure.ai.

TypeEmerging player
Description

AI-driven cardiac diagnostics (FFR-CT) for coronary artery disease; comparable as a specialty AI imaging company with regulatory clearances, hospital system sales motion, and clinical-evidence-led go-to-market akin to Qure.ai's heart-failure and lung nodule modules.

TypeDirect peer
Description

Specialist in AI-powered stroke detection and care coordination on head CT, the most direct competitor to Qure.ai's qER for stroke triage and hub-and-spoke workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers37 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qure AI

Medical Imaging AIqure.ai

Qure.ai is a Mumbai-headquartered healthcare AI company that builds FDA-cleared deep-learning algorithms to interpret chest X-rays, head CTs, chest CTs, and ultrasounds, deployed across 5,500+ sites in 105+ countries via direct hospital sales, OEM embedding, and government public-health programs.

What Qure AI does

Qure.ai Technologies Private Limited is a Mumbai-headquartered healthcare AI company founded in 2016 by Prashant Warier that develops deep-learning computer-vision models for automated interpretation of radiology exams (chest X-ray, head CT, chest CT, MSK X-ray) and, more recently, ultrasound. Its product portfolio is anchored by qXR (chest X-ray reporting with 26 FDA-cleared indications across 9 products), supported by qER (stroke/TBI head CT), qCT LN Quant (lung nodule management), qMSK, qTrack (care coordination), qScout (population surveillance), and the Aira clinical AI co-pilot for LMICs; algorithms are trained on more than 1 billion medical images and are deployed as cloud or on-premise services integrated with PACS/RIS and OEM imaging platforms.

The company monetizes primarily through enterprise SaaS subscriptions to hospital systems and NHS trusts, per-study/per-deployment licensing to OEM and platform partners (Fujifilm, Siemens Healthineers, Philips, Blackford, Medtronic, Nuance), managed-services contracts with national and state public health programs (Telangana, Goa, Maharashtra, Lesotho, Mozambique, Oman), professional-services arrangements with pharma and life-sciences customers (AstraZeneca, Project Data Sphere, Roche Startup Creasphere), and non-dilutive grant funding (Gates Foundation $8M, SBRI/NHS £3.2M). Its go-to-market combines direct enterprise sales (partner@qure.ai) with OEM embedding, channel resellers (Medica Group, InHealth, USARAD, Strategic Radiology, Unilabs, deepc, Healthcare Imaging Services), NGO/global-health partners (PATH, VillageReach, IHVN, CIDRZ), and event-led demand generation across RSNA, ASCO, ATS, and the India AI Impact Summit.

Qure.ai reports reaching 45M+ lives across 105+ countries via 5,500+ sites, holds 40 patents, and is referenced in a 2026 source as a subsidiary of Fractal Analytics; it has raised approximately $130M cumulatively, including a $65M Series D in September 2024 led by Lightspeed and 360 ONE Asset. The company maintains offices in Mumbai, Bengaluru, New York, and Birmingham, and counts the FDA, EU MDR, Health Canada, and the WHO (for autonomous TB screening) among its regulatory endorsements.

Qure AI firmographics

Firmographics
Name
Qure AI
Legal name
Qure.ai Technologies Private Limited
Website
https://qure.ai
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Qure.ai is a Mumbai-headquartered healthcare AI company that builds FDA-cleared deep-learning algorithms to interpret chest X-rays, head CTs, chest CTs, and ultrasounds, deployed across 5,500+ sites in 105+ countries via direct hospital sales, OEM embedding, and government public-health programs.
Ownership category
akta.pro rank

Qure AI industry classification

Industry
Product category
Medical Imaging AI
NAICS
Software Publishers (51321), Diagnostic Imaging Centers (621512)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Medical imaging AI
  • Radiology AI software
  • Clinical decision support
  • Lung cancer detection
  • Tuberculosis screening

Where Qure AI is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Qure AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Enterprise SaaS subscriptions: Subscription-based deployment of qXR, qER, qCT, qTrack, and qMSK AI platforms to hospital systems, NHS trusts, teleradiology firms, and government health programs. Recurring contracts tied to deployment scope, volume, and integrations.
  2. OEM/embedded licensing: Per-study/per-deployment licensing to OEM and platform partners including Fujifilm (REiLI), Siemens Healthineers, Philips, Blackford, Medtronic, and Nuance, who embed Qure.ai algorithms into their own products and services.
  3. Government and public health program contracts: Direct contracts with state health ministries and national TB/lung cancer programs (Telangana, Goa, Maharashtra, Bihar, Lesotho, South Africa, Mozambique, Philippines) for population-scale AI screening deployments.
  4. Pharma & life sciences clinical trial services: AI-derived biomarker and care coordination services for pharmaceutical R&D and clinical trials, including partnership with Project Data Sphere on autoRECIST for tumor burden measurement and AstraZeneca A.Catalyst Network collaborations.
  5. Grants and non-dilutive funding: Multi-million-dollar grants from foundations such as the Gates Foundation ($8M for AI-powered point-of-care ultrasound and open-source multi-modal lung health database) and SBRI Healthcare / NHS Cancer Programme (£3.2M).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise contracts via partner@qure.ai

Go-to-market motion5 records

Distribution channels5 records

Marketing channels8 records

Qure AI product offering

Product offering

Core offering

Qure AI develops deep-learning medical imaging software that interprets chest X-rays, head CTs, chest CTs, and musculoskeletal X-rays for clinical decision support. Its portfolio (qXR, qER, qCT LN Quant, qTrack, qMSK, Aira, qXR-CTR) is sold to hospitals, NHS trusts, teleradiology firms, government public-health programs, OEM imaging vendors, and pharmaceutical/life-sciences organizations.

Product overview

Qure.ai offers a single unified AI healthcare platform combining a portfolio of deep-learning medical imaging products deployed across 5,500+ sites in 105+ countries. The portfolio is anchored by qXR (chest X-ray reporting) as the core imaging product, supported by qER (stroke and TBI head CT analysis), qMSK (musculoskeletal X-ray), and Heart Failure (qXR-CTR) modules, with qTrack providing care coordination and TB cascade management. The Lung Nodule Management module (including qCT LN Quant) extends the platform to end-to-end lung cancer care, while Aira acts as a multi-disease clinical AI co-pilot for resource-constrained settings. Together these products cover the full clinical workflow from screening and triage to diagnosis, quantification, and longitudinal case management.

Differentiator

Problem solved

Functional benefit

Brands

  • qXR: Chest X-ray AI reporting and triage solution; includes sub-products such as qXR-Detect, qXR-LN (lung nodule detection), qXR-PTX-PE (pneumothorax and pleural effusion), and qXR-CTR (heart failure risk indicator).
  • qTrack
  • qER
  • qMSK
  • qCT LN Quant
  • Aira
  • qScout
  • Qure AI App

Products and services

  • qXR (Chest X-ray Reporting)
  • qER (Stroke & Traumatic Brain Injury)
  • Lung Nodule Management (qCT LN Quant)
  • qTrack (TB Care Cascades)
  • qMSK (Musculoskeletal X-Ray Reporting)
  • Heart Failure (qXR-CTR)
  • Aira (Multi-Disease Clinical AI Co-Pilot)
  • Qure AI App

Quantifiable outcome

  • 26.7% of initially missed lung nodules detected on routine chest X-rays using qXR-LN, including 40% of early-stage cancers and 50% of missed Stage 1A nodules (University Hospitals Cleveland Medical Center study)
  • +9 more outcomes

Companies that use Qure AI

Customer profile

Named customers37 records

Segments6 records

Ideal customer profiles5 records

Qure AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability10 records

Feature8 records

Qure AI partnerships and signals

Strategic signal

Partnerships

33 partnerships are on record, tiered flagship, core and minor.

  • AstraZenecaflagshipStrategic or Co-development PartnerMulti-program strategic partnership under the EDISON Alliance's 1 Billion Lives Challenge to screen 5 million patients by 2025 for lung cancer risk in Colombia, El Salvador, India, and other LMICs. Joint lung cancer screening programs in Telangana (20 hospitals), Goa, Philippines, and Latin America. Co-development of A.Catalyst Network initiatives and combined pharma-AI care pathways.
  • MicrosoftflagshipStrategic or Co-development PartnerPartnership to expand access to Qure.ai's lung cancer detection and management suite in the United States (announced November 2025). Joint go-to-market leveraging Microsoft's cloud and healthcare channels for US-based deployments.
  • Medtronic IndiacoreStrategic or Co-development PartnerHub-and-spoke stroke care partnership in India integrating Qure.ai's AI CT analysis with Medtronic's stroke network to expedite treatment for nearly two million stroke patients annually.
  • Project Data SpherecoreStrategic or Co-development PartnerCo-developing autoRECIST AI for imaging-based tumor burden measurements in oncology clinical trials and routine cancer care, announced January 2024.
  • Roche (Startup Creasphere APAC)coreStrategic or Co-development PartnerJoined Roche's Startup Creasphere APAC program to co-create strategies supporting clinicians and improving patient outcomes in APAC through early detection enabled by AI (October 2024).
  • Johnson & Johnson MedtechcoreStrategic or Co-development PartnerPartnership to boost early detection of lung cancer in India, integrating Qure.ai AI solutions with J&J Medtech lung cancer initiatives (announced May 2025).
  • FujifilmflagshipOEM/ Whitelabel/ Licensing PartnerValidated on Fujifilm's AI-enabled platform REiLI and partnered with Fujifilm and IHVN to accelerate TB screening in rural Nigerian communities (2021, 2023). Co-delivered solutions across global health programs.
  • Siemens HealthineersflagshipOEM/ Whitelabel/ Licensing PartnerValidated partner on Siemens Healthineers AI portfolio; collaboration with the Global Fund to accelerate AI adoption for TB diagnosis (2023); recipient of Siemens Healthineers Startup Award 2024.
  • PhilipscoreTechnology or IntegrationPartner logo displayed on the Qure.ai homepage indicating technology integration and co-distribution across Philips imaging and AI portfolio.
  • Blackford AnalysiscoreChannel Partner/ Reseller/ DistributorListed as a distribution/integration partner on the Qure.ai homepage, deploying Qure.ai neurocritical AI solutions into A&E settings including Milton Keynes University Hospital.
  • VillageReachcoreStrategic or Co-development PartnerPartnership to strengthen Mozambique's AI-enabled pandemic preparedness system, announced May 2026.
  • Horizon Health Network (Canada)coreImplementation/ SI/ Consulting PartnerProvince-wide partnership to advance early lung cancer detection across New Brunswick, Canada, announced December 2025.
  • Yashoda Hospital Hitech CitycoreStrategic or Co-development PartnerLaunched an AI-enabled Lung Nodule Clinic with Qure.ai to strengthen early lung cancer detection and lung health, announced November 2025.
  • PenRAD Imaging NetworkminorChannel Partner/ Reseller/ DistributorDeployed AI-Powered Chest CT for early lung cancer detection via Qure.ai, announced April 2025.
  • Government of Goa (India)flagshipStrategic or Co-development PartnerPublic-private partnership with AstraZeneca and Qure.ai to perform AI-enabled chest X-ray screening; over 1 lakh X-rays reviewed identifying 18 lung cancer cases. Extended MoU announced April 2025.
  • Government of Telangana (India)flagshipStrategic or Co-development PartnerMoU with AstraZeneca Pharma India and Qure.ai to deploy AI-powered lung cancer screening across 20 public hospitals, announced April 2026.
  • Erasmus MC (Rotterdam)coreStrategic or Co-development PartnerLaunched AI Innovation Centre for Medical Imaging in September 2022 and extended collaboration in December 2024 for early lung cancer detection.
  • deepccoreChannel Partner/ Reseller/ DistributorPartnership to empower care teams with AI-enhanced patient care workflows by integrating Qure.ai AI into deepc's platform (November 2023).
  • Nuance (Microsoft)coreChannel Partner/ Reseller/ DistributorJoined Nuance Precision Imaging Network to enhance patient outcomes with AI-integrated workflows for care teams (April 2023).
  • Medica GroupcoreChannel Partner/ Reseller/ DistributorStrategic partnership integrating Qure.ai augmented intelligence into Medica Group's teleradiology services for the UK, supporting faster stroke and neurocritical reporting.
  • InHealth (UK)minorChannel Partner/ Reseller/ DistributorPartnership to enhance quality of telereporting services with Qure.ai's AI-powered chest X-ray solution (May 2023).
  • USARADminorChannel Partner/ Reseller/ DistributorPartnership expanded Qure.ai presence into US teleradiology market (October 2023).
  • Strategic Radiology (US)minorChannel Partner/ Reseller/ DistributorCollaboration to assist radiology workflows with Qure.ai AI-powered imaging (June 2024).
  • UnilabsminorChannel Partner/ Reseller/ DistributorUnilabs signed on Qure.ai for triaging chest X-rays (July 2022).
  • TherapixelminorStrategic or Co-development PartnerPartnership to improve access to breast cancer detection through AI (March 2023).
  • xWave TechnologiesminorChannel Partner/ Reseller/ DistributorStrategic collaboration announced August 2023.
  • Healthcare Imaging Services (Australia)minorChannel Partner/ Reseller/ DistributorPartnership to bring AI chest X-ray diagnosis to Australia (July 2021).
  • Nordic MedTechminorChannel Partner/ Reseller/ DistributorPartnership to provide radiology practices with Qure.ai AI technology (July 2020).
  • PATH IndiacoreImplementation/ SI/ Consulting PartnerImplementation partner for AI-enabled chest X-ray solution for TB and COVID-19 screening in Maharashtra through Unitaid funding (2021-2023). Joint lung cancer early detection initiative with AstraZeneca in LMICs (2022).
  • USAIDcoreStrategic or Co-development PartnerUSAID-supported SAMRIDH Healthcare Blended Finance Facility supports Qure.ai to strengthen India's healthcare systems (April 2022); joint program to enhance diagnostics (September 2023).
  • IHVN (Institute of Human Virology Nigeria)minorImplementation/ SI/ Consulting PartnerPartnered with Fujifilm and Qure.ai to accelerate TB screening in rural Nigerian communities (August 2022).
  • CIDRZ (Centre for Infectious Disease Research in Zambia)minorImplementation/ SI/ Consulting PartnerPartnered with Qure.ai for TB screening (July 2022).
  • Fractal AnalyticsflagshipStrategic or Co-development PartnerQure.ai is referenced as a Fractal Analytics subsidiary in Fractal's Q4 FY26 commentary (May 2026). Fractal showcased a partnership with Qure.ai for rapid TB detection in radiology at the India AI Impact Summit 2026.

Scale indicators20 records

Recent moves8 records

Expansion highlights8 records

Qure AI competitors and assessment

Company assessment

Direct peers

  • Lunit: South Korea-based AI medical imaging company with flagship INSIGHT CXR for chest X-ray triage and Lunit SCOPE for biomarker analysis — directly competing with Qure.ai's qXR in chest X-ray AI for lung cancer and TB detection across hospital systems.
  • Nanox AI (formerly Zebra Medical Vision): AI imaging algorithms for chest, bone, and other modalities distributed through the Nanox platform; overlaps with Qure.ai's qXR chest X-ray and broader imaging AI footprint.
  • Aidoc: AI medical imaging company offering a suite of FDA-cleared algorithms for CT/MRI triage across multiple findings; directly comparable to Qure.ai's qER and broader imaging AI strategy aimed at hospital radiology workflows.
  • Annalise.ai: Comprehensive AI radiology platform covering chest X-ray, CT, and head CT findings — closely comparable to Qure.ai's multi-modality imaging portfolio and enterprise hospital go-to-market.
  • Viz.ai: Specialist in AI-powered stroke detection and care coordination on head CT, the most direct competitor to Qure.ai's qER for stroke triage and hub-and-spoke workflow.

Others

  • Blackford Analysis: Medical imaging AI aggregator and distribution platform that resells/embeds Qure.ai algorithms alongside competitor algorithms; relevant as a channel peer and AI marketplace operator shaping hospital AI procurement.

Emerging players

  • Therapixel: AI mammography (MammoScreen) and breast cancer detection — overlaps with Qure.ai's life sciences and screening thesis; also a named Qure.ai partner, indicating close ecosystem positioning.
  • HeartFlow: AI-driven cardiac diagnostics (FFR-CT) for coronary artery disease; comparable as a specialty AI imaging company with regulatory clearances, hospital system sales motion, and clinical-evidence-led go-to-market akin to Qure.ai's heart-failure and lung nodule modules.

Broad incumbents

  • Philips: Global imaging and health technology incumbent with its own AI imaging suite; operates as a Qure.ai technology and distribution partner, and competes broadly in radiology AI decision support.
  • Siemens Healthineers: Global imaging modality OEM with its own AI-Rad Companion portfolio and validated-Qure.ai partner on REiLI equivalent; relevant as both a broad incumbent competitor and an OEM distribution channel for Qure.ai.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Qure AI social profiles

Digital presence

Qure AI compliance and trust

Trust signal

Compliance6 records

Qure AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qure AI leadership team

Management profile

Number of profiles

Profiles15 records

Qure AI subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Qure AI funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qure AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qure AI

What does Qure AI do?

Qure AI develops deep-learning medical imaging software that interprets chest X-rays, head CTs, chest CTs, and musculoskeletal X-rays for clinical decision support. Its portfolio (qXR, qER, qCT LN Quant, qTrack, qMSK, Aira, qXR-CTR) is sold to hospitals, NHS trusts, teleradiology firms, government public-health programs, OEM imaging vendors, and pharmaceutical/life-sciences organizations.

Is Qure AI a public or private company?

Qure AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qure AI founded?

Qure AI was founded in 2016. It employs 251 to 500 people.

Where is Qure AI based?

Qure AI is headquartered in New York, United States, in the North America region.

How does Qure AI make money?

Five revenue lines are on record. Enterprise SaaS subscriptions are the primary driver. The others are OEM/embedded licensing, government and public health program contracts, pharma & life sciences clinical trial services and grants and non-dilutive funding.

Who are Qure AI's main competitors?

Direct peers on record are Lunit, Nanox AI (formerly Zebra Medical Vision), Aidoc, Annalise.ai and Viz.ai. Blackford Analysis is listed as an others. Emerging players are Therapixel and HeartFlow. Broad incumbents are Philips and Siemens Healthineers.

Does Qure AI have an API?

No public API is recorded for Qure AI.

What industry is Qure AI in?

Qure AI's product category is Medical Imaging AI. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 51321 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Fortune IndiaMumbai start-up Qure.ai leads global automated TB screening; develops AI diagnosing tools for lung cancer, heart diseasesMumbai start-up Qure.ai developed an AI tool for automated TB screening that is one of three WHO-evaluated solutions, adopted in over 100 countries. The company has raised $123 million and is close to profitability, with half its revenue from TB diagnosis and half from other AI applications.Fortune IndiaMumbai start-up Qure.ai leads global automated TB screening; develops AI diagnosing tools for lung cancer, heart diseasesMumbai startup Qure.ai's AI tool for automated TB screening, evaluated by the WHO, is used in over 100 countries. The company has raised $123 million and reports half its revenue from TB diagnosis, with plans to reach profitability within six months.https://www.outlookbusiness.com/India Must Move Beyond The ‘AI Application Edge’ Narrative And Build Foundational Strength – Outlook BusinessIndia's AI investment is concentrated in application-layer start-ups, but they lag US and Chinese peers in revenue. Nearly 80% of AI funding goes to apps, yet Indian start-ups like Qure.ai raise far less than US counterparts. The article argues India must build foundational strength and risk-taking culture to close the gap.CXOToday.comIndian AI Startups Taking on Global Tech GiantsIndian AI startups KOGO AI, Sarvam AI, CoRover, and Qure.ai are challenging global tech giants by solving local problems like private AI deployment, Indian-language speech, and TB screening. KOGO offers private agentic AI, Sarvam supports 22 Indian languages, CoRover serves public digital infrastructure, and Qure.ai's qXR achieved a 90.81% ROC score in TB screening.Built In15 Top AI Companies in MumbaiFour AI companies in Mumbai are profiled: InVideo, Fractal Analytics, Miko, and Qure.ai. InVideo automates video creation, Fractal offers enterprise AI consulting, Miko builds AI companion robots, and Qure.ai develops medical image analysis software.PR Newswire APACQure.ai's Clinical Decision Support System Aira Among World's First to Win Class IIb CE CertificationQure.ai announced that its Aira clinical decision support system received Class IIb CE certification under the EU Medical Device Regulation. The system, built for primary care in emerging economies, has been piloted in Nigeria, Kenya, Mozambique, the Solomon Islands, and Bangladesh, with documented improvements in documentation time and patient-facing care time.Digital Health NewsAstraZeneca India & Andhra Gov Inks MoU to Launch AI, Genomics & Precision Oncology EcosystemThe Government of Andhra Pradesh signed a MoU with AstraZeneca India to launch India's first integrated Precision Oncology ecosystem, combining AI, genomics, and Next Generation Sequencing technologies through Amaravati Quantum Valley. AstraZeneca India will collaborate with Reliance-backed Strand Life Sciences and health-tech firm Qure.ai to establish an Integrated Genomic Solutions Centre providing NGS-based biomarker testing for lung and breast cancer patients, along with AI-enabled X-ray screening systems in government hospitals. The initiative includes complimentary biomarker testing during the initial phase to improve access to advanced genomic diagnostics for cancer patients.The Hans IndiaPrecision oncology move to put Amaravati on India's genomics mapAndhra Pradesh's Health Department and AstraZeneca India signed an MoU to establish an Integrated Genomics Solutions Center in Amaravati, marking India's first integrated precision oncology initiative. The project, with Strand Life Sciences and Qure.ai, will use NGS, AI, and diagnostics for lung and breast cancer, deploying AI-powered chest X-ray systems for early detection.AuntMinnieQure.ai names new sales, marketing leadersQure.ai has promoted Amy Casey to executive vice president of sales for North America and appointed Malika Shrivastava as its first chief marketing officer. Casey will lead the vendor's commercial strategy in the region, while Shrivastava will oversee global marketing operations including brand and product marketing.www.bestmediainfo.comQure.ai appoints Malika Shrivastava as Chief Marketing OfficerQure.ai appointed Malika Shrivastava as its first Chief Marketing Officer and promoted Amy Casey to Executive Vice President of Sales for North America. These leadership additions are intended to strengthen the company's commercial capabilities and support its expansion in the United States healthcare market.